Association between TNF-α promoter -308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 37, Issue 1, 2012, Pages 106-110

  Wang, Fan ^a,b   Fan, Hongzhen ^b   Sun, Hongqiang ^b   Yang, Fude ^b   Luo, Yixiao ^a   Liu, Haibo ^b   Kosten, Thomas R ^c   Lu, Lin ^a   Zhang, Xiang Yang ^b,c  

^a PEKING UNIVERSITY   (China)

^b BEIJING HUILONGGUAN HOSPITAL   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Association; Polymorphism; Schizophrenia; Tardive dyskinesia; Tumor necrosis factor

Indexed keywords

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGED; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POSITIVE AND NEGATIVE SYNDROME SCALE; PROMOTER REGION; RATING SCALE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA; TUMOR NECROSIS FACTOR ALPHA GENE;

ADENOSINE; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GUANINE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; QUESTIONNAIRES; SCHIZOPHRENIA; SINGLE-BLIND METHOD; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862786198     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.12.007     Document Type: Article

References (46)

1. Alberts B., Wilson J.H., Hunt T. Molecular biology of the cell 2008, Abingdon: Garland Science, New York, N.Y, Reference ed. ed. 5th ed.
2. Bentley G., Higuchi R., Hoglund B., Goodridge D., Sayer D., Trachtenberg E.A., et al. High-resolution, high-throughput HLA genotyping by next-generation sequencing. Tissue Antigens 2009, 74:393-403.
3. Bishnoi M., Chopra K., Kulkarni S.K. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1473-1478.
4. Blanchard J.J., Brown S.A., Horan W.P., Sherwood A.R. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin Psychol Rev 2000, 20:207-234.
5. Boin F., Zanardini R., Pioli R., Altamura C.A., Maes M., Gennarelli M. Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry 2001, 6:79-82.
6. Brown K.W., White T. Human leucocyte antigens and tardive dyskinesia. Br J Psychiatry 1991, 158:270-272.
7. Caligiuri M.P., Lacro J.P., Rockwell E., McAdams L.A., Jeste D.V. Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry 1997, 171:148-153.
8. Canoso R.T., Romero J.A., Yunis E.J. Immunogenetic markers in chlorpromazine-induced tardive dyskinesia. J Neuroimmunol 1986, 12:247-252.
9. Chen J., Zheng H., Bei J.X., Sun L., Jia W.H., Li T., et al. Genetic structure of the Han Chinese population revealed by genome-wide SNP variation. Am J Hum Genet 2009, 85:775-785.
10. Czerski P.M., Rybakowski F., Kapelski P., Rybakowski J.K., Dmitrzak-Weglarz M., Leszczynska-Rodziewicz A., et al. Association of tumor necrosis factor -308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology 2008, 57:88-94.
11. Damle R.N., Advani S.H., Gangal S.G. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease. Int J Cancer 1992, 50:192-196.
12. Davis K.L. Neuropsychopharmacology: the fifth generation of progress: an official publication of the American College of Neuropsychopharmacology 2002, Lippincott/Williams & Wilkins, Philadelphia; London.
13. Duan S., Xu Y., Chen W., Liu Z., Guo T., Gao J., et al. No association between the promoter variants of tumor necrosis factor alpha (TNF-alpha) and schizophrenia in Chinese Han population. Neurosci Lett 2004, 366(2):139-143.
14. Ghaemi S.N., Hsu D.J., Rosenquist K.J., Pardo T.B., Goodwin F.K. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:209-213.
15. Hajeer A.H., Hutchinson I.V. TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech 2000, 50:216-228.
16. Kim Y.J., Lee H.S., Yoon J.H., Kim C.Y., Park M.H., Kim L.H., et al. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003, 12:2541-2546.
17. Lee P.E., Sykora K., Gill S.S., Mamdani M., Marras C., Anderson G., et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 2005, 53:1374-1379.
18. Li C.R., Chung Y.C., Park T.W., Yang J.C., Kim K.W., Lee K.H., et al. Clozapine-induced tardive dyskinesia in patients with schizophrenia taking clozapine as a first-line antipsychotic drug. World J Biol Psychiatry 2009, 10:919-924.
19. Liu H., Wang C., Chen P.H., Zhang B.S., Zheng Y.L., Zhang C.X., et al. Association of the manganesesuperoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:692-696.
20. Liu L., Jia F., Yuan G., Chen Z., Yao J., Li H., et al. Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis. Psychiatry Res 2010, 176:1-7.
21. Marsh S.G.E., Parham P., Barber L.D. The HLA factsbook 2000, London: Academic, San Diego, Calif.
22. McCreadie R.G., Thara R., Kamath S., Padmavathy R., Latha S., Mathrubootham N., et al. Abnormalmovements in never-medicated Indian patients with schizophrenia. Br J Psychiatry 1996, 168:221-226.
23. Metzer W.S., Newton J.E., Steele R.W., Claybrook M., Paige S.R., McMillan D.E., et al. HLA antigensin tardive dyskinesia. J Neuroimmunol 1990, 26:179-181.
24. Moots R.J., Al-Saffar Z., Hutchinson D., Golding S.P., Young S.P., Bacon P.A., et al. Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis 1999, 58:585-587.
25. Morar B., Schwab S.G., Albus M., Maier W., Lerer B., Wildenauer D.B. Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:318-324.
26. Mukherjee S., Mahadik S.P., Korenovsky A., Laev H., Schnur D.B., Reddy R. Serum antibodies to nicotinic acetylcholine receptors in patients with schizophrenia. Schizophr Res 1994, 12:131-136.
27. Muller D.J., Schulze T.G., Knapp M., Held T., Krauss H., Weber T., et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001, 104:375-379.
28. Muller D.J., Shinkai T., De Luca V., Kennedy J.L. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 2004, 4:77-87.
29. Naz M., Riaz M., Saleem M. Potential role of Neuregulin 1 and TNF-alpha (-308) polymorphism in schizophrenia patients visiting hospitals in Lahore, Pakistan. Mol Biol Rep 2011, 38:4709-4714.
30. Nedwin G.E., Svedersky L.P., Bringman T.S., Palladino M.A., Goeddel D.V. Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol 1985, 135:2492-2497.
31. O'Brien S.M., Scully P., Dinan T.G. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res 2008, 160:256-262.
32. Pacheco P.R., Branco C.C., Gomes C.T., Cabral R., Mota-Vieira L. HLA class I and II profiles in Sao Miguel Island (Azores): genetic diversity and linkage disequilibrium. BMC Res Notes 2010, 3:134.
33. Rapaport M.H., Lohr J.B. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 1994, 90:311-315.
34. Rapaport M.H., Caligiuri M.P., Lohr J.B. An association between increased serum-soluble interleukin-2 receptors and a disturbance in muscle force in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1997, 21:817-827.
35. Riedel M., Kronig H., Schwarz M.J., Engel R.R., Kuhn K.U., Sikorski C., et al. No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. Eur Arch Psychiatry Clin Neurosci 2002, 252:232-234.
36. Sacchetti E., Bocchio-Chiavetto L., Valsecchi P., Scassellati C., Pasqualetti P., Bonvicini C., et al. G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: meta-analysis plus association study. Brain Behav Immun 2007, 21:450-457.
37. Peltonen Schizophrenia L. All out for chromosome six. Nature 1995, 378:665-666.
38. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982, 39:486-487.
39. Tian W., Zeng X.M., Li L.X., Jin H.K., Luo Q.Z., Wang F., et al. Gender-specific associations between MICA-STR and nasopharyngeal carcinoma in a southern Chinese Han population. Immunogenetics 2006, 58:113-121.
40. Turbay D., Lieberman J., Alper C.A., Delgado J.C., Corzo D., Yunis J.J., et al. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood 1997, 89:4167-4174.
41. van Os J., Fahy T., Jones P., Harvey I., Toone B., Murray R. Tardive dyskinesia: who is at risk?. Acta Psychiatr Scand 1997, 96:206-216.
42. van Os J., Walsh E., van Horn E., Tattan T., Bale R., Thompson S.G. Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group. Acta Psychiatr Scand 2000, 101:300-306.
43. Wang Y.C., Bai Y.M., Chen J.Y., Lin C.C., Lai I.C., Liou Y.J. Genetic association between TNF-alpha -308 G>A polymorphism and longitudinal weight change during clozapine treatment. Hum Psychopharmacol 2010, 25:303-309.
44. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997, 94:3195-3199.
45. Wu Y.R., Feng I.H., Lyu R.K., Chang K.H., Lin Y.Y., Chan H., et al. Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:300-304.
46. Yarlagadda A., Helvink B., Chou C., Gladieux K., Keller A., Clayton A. Glutamic acid decarboxylase (GAD) antibodies in tardive dyskinesia (TD) as compared to patients with schizophrenia without TD and normal controls. Schizophr Res 2008, 105:287-288.